Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01294410




Registration number
NCT01294410
Ethics application status
Date submitted
10/02/2011
Date registered
11/02/2011
Date last updated
25/06/2015

Titles & IDs
Public title
Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis
Scientific title
A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC)
Secondary ID [1] 0 0
2010-022506-41
Secondary ID [2] 0 0
IM129-005
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colitis, Ulcerative 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Anti-IP-10 Antibody
Treatment: Drugs - Anti-IP-10 Antibody
Treatment: Drugs - Anti-IP-10 Antibody
Treatment: Drugs - Anti-IP-10 Antibody
Treatment: Drugs - Anti-IP-10 Antibody
Treatment: Drugs - Anti-IP-10 Antibody

Experimental: Cohort 1: Induction - Placebo or Anti-IP-10 Antibody

Experimental: Cohort 2: Induction - Placebo or Anti-IP-10 Antibody

Experimental: Cohort 3: Induction - Placebo or Anti-IP-10 Antibody

Experimental: Maintenance - Placebo or Anti-IP-10 Antibody

Other: Open Label -


Treatment: Drugs: Placebo
Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks

Treatment: Drugs: Placebo
Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days

Treatment: Drugs: Anti-IP-10 Antibody
Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks

Treatment: Drugs: Anti-IP-10 Antibody
Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks

Treatment: Drugs: Anti-IP-10 Antibody
Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days

Treatment: Drugs: Anti-IP-10 Antibody
Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days

Treatment: Drugs: Anti-IP-10 Antibody
Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days

Treatment: Drugs: Anti-IP-10 Antibody
Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of the subjects with clinical remission (defined as Mayo score = 2 points with no individual subscore > 1 point) of BMS-936557 with that of the placebo
Timepoint [1] 0 0
End of Induction [Week 11, Induction Period-78 (IP-78)]
Secondary outcome [1] 0 0
Proportion of the subjects with clinical response of BMS-936557 with that of the placebo
Timepoint [1] 0 0
IP-78 (Week 11)
Secondary outcome [2] 0 0
Proportion of subjects with mucosal healing (defined as endoscopy subscore of =1 point) of BMS-936557 with that of the placebo
Timepoint [2] 0 0
IP-78 (Week 11)
Secondary outcome [3] 0 0
Proportion of subjects reporting Adverse event (AE), Serious adverse events (SAEs), AEs leading to discontinuation, and markedly abnormal laboratory values
Timepoint [3] 0 0
IP-78 (Week 11)
Secondary outcome [4] 0 0
Mean change from baseline at Inflammatory Bowel Disease Questionnaire (IBDQ) of subjects treated with BMS-936557 and placebo
Timepoint [4] 0 0
Baseline (IP-1, Week 1) and IP-78 (Week 11)

Eligibility
Key inclusion criteria
- Clinical diagnosis of moderate to severe UC confirmed by endoscopic and histologic
evidence

- Mayo score =6 with an endoscopic subscore of =2

- Inadequate response and/or intolerance to one or more conventional therapy (i.e. oral
aminosalicylates, immunosuppressants, corticosteroids, and/or TNF antagonist)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Diagnosis of Crohn's Disease or Indeterminate Colitis

- Diagnosis of UC that is limited to the rectum

- Evidence of fulminant colitis, toxic megacolon, or bowel perforation

- Current need for a colostomy or ileostomy

- Previous total or subtotal colectomy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2014
Sample size
Target
Accrual to date
Final
305
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - Garran
Recruitment hospital [2] 0 0
Local Institution - Concord
Recruitment hospital [3] 0 0
Local Institution - Herston
Recruitment hospital [4] 0 0
Local Institution - Parkville
Recruitment hospital [5] 0 0
Local Institution - South Brisbane
Recruitment hospital [6] 0 0
Local Institution - Fremantle
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
4029 - Herston
Recruitment postcode(s) [4] 0 0
3050 - Parkville
Recruitment postcode(s) [5] 0 0
4101 - South Brisbane
Recruitment postcode(s) [6] 0 0
6959 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Rhode Island
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
Austria
State/province [17] 0 0
Graz
Country [18] 0 0
Austria
State/province [18] 0 0
Vienna
Country [19] 0 0
Belgium
State/province [19] 0 0
Bonheiden
Country [20] 0 0
Belgium
State/province [20] 0 0
Edegem
Country [21] 0 0
Belgium
State/province [21] 0 0
Leuven
Country [22] 0 0
Brazil
State/province [22] 0 0
Goias
Country [23] 0 0
Brazil
State/province [23] 0 0
Sao Paulo
Country [24] 0 0
Brazil
State/province [24] 0 0
Rio De Janeiro
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
British Columbia
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
France
State/province [28] 0 0
Clichy
Country [29] 0 0
France
State/province [29] 0 0
Lille Cedex
Country [30] 0 0
France
State/province [30] 0 0
Nice
Country [31] 0 0
France
State/province [31] 0 0
Pessac
Country [32] 0 0
France
State/province [32] 0 0
Vandoeuvre Les Nancy
Country [33] 0 0
Germany
State/province [33] 0 0
Hamburg
Country [34] 0 0
Germany
State/province [34] 0 0
Kiel
Country [35] 0 0
Germany
State/province [35] 0 0
Muenster
Country [36] 0 0
Hungary
State/province [36] 0 0
Budapest
Country [37] 0 0
Hungary
State/province [37] 0 0
Debrecen
Country [38] 0 0
Hungary
State/province [38] 0 0
Szeged
Country [39] 0 0
Italy
State/province [39] 0 0
Padova
Country [40] 0 0
Italy
State/province [40] 0 0
Roma
Country [41] 0 0
Italy
State/province [41] 0 0
San Donato Milanese (mi)
Country [42] 0 0
Italy
State/province [42] 0 0
San Giovanni Rotondo (fg)
Country [43] 0 0
Mexico
State/province [43] 0 0
Distrito Federal
Country [44] 0 0
Mexico
State/province [44] 0 0
Jalisco
Country [45] 0 0
Mexico
State/province [45] 0 0
Nuevo Leon
Country [46] 0 0
Mexico
State/province [46] 0 0
Veracruz
Country [47] 0 0
Netherlands
State/province [47] 0 0
Amsterdam
Country [48] 0 0
Netherlands
State/province [48] 0 0
Rotterdam
Country [49] 0 0
Poland
State/province [49] 0 0
Rzeszow
Country [50] 0 0
Poland
State/province [50] 0 0
Sosnowiec
Country [51] 0 0
Poland
State/province [51] 0 0
Warszawa
Country [52] 0 0
South Africa
State/province [52] 0 0
Kwa Zulu Natal
Country [53] 0 0
South Africa
State/province [53] 0 0
Western Cape
Country [54] 0 0
South Africa
State/province [54] 0 0
Paarl

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether BMS-936557 is effective in the treatment of
moderate to severely active ulcerative colitis in patients who have had insufficient response
and/or intolerance to other medical therapy for ulcerative colitis
Trial website
https://clinicaltrials.gov/ct2/show/NCT01294410
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01294410